Patents-Review.com
ClassID:

21152 ⎘

A61K39/39566 - CPC Classification

Classification description:

Medicinal preparations containing antigens or antibodies; Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies

Recent Application in this class:
#1
20260092105
2026-04-02

ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE

 #2
20250388700
2025-12-25

VARIANT FC REGIONS

 #3
20250388699
2025-12-25

VARIANT FC REGIONS

 #4
20250360208
2025-11-27

USE OF GLUTAMATE MODULATING AGENTS WITH IMMUNOTHERAPIES TO TREAT CANCER

 #5
20250295768
2025-09-25

METHODS OF TREATING AUTOIMMUNE AND ALLOIMMUNE DISORDERS

 #6
20250213684
2025-07-03

COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3

 #7
20250177523
2025-06-05

MULTISPECIFIC ANTIGEN-BINDING PROTEINS

 #8
20250170108
2025-05-29

CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND

 #9
20250032610
2025-01-30

MULTISPECIFIC ANTIGEN-BINDING PROTEINS

 #10
20240309101
2024-09-19

ANTI-CD25 ANTIBODY AGENTS

 #11
20240293415
2024-09-05

COMBINATION THERAPIES

 #12
20240279322
2024-08-22

ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE

 #13
20240269279
2024-08-15

PHARMACEUTICAL FORMULATION CONTAINING AN ANTI-IgE ANTIBODY

 #14
20240150494
2024-05-09

GLYCOFORM SPECIFIC NANOBODIES AND METHODS OF USE

 #15
20240148845
2024-05-09

GENETICALLY MODIFIED ANTI-THIRD PARTY CENTRAL MEMORY T CELLS AND USE OF SAME IN IMMUNOTHERAPY

 #16
20240076387
2024-03-07

ANTI-FLT-1 ANTIBODIES FOR TREATING DUCHENNE MUSCULAR DYSTROPHY

 #17
20240075151
2024-03-07

CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS

 #18
20240050437
2024-02-15

HETEROCYCLIC COMPOUNDS AND USES THEREOF

 #19
20230390370
2023-12-07

NEOANTIGEN VACCINES FOR PANCREATIC CANCER

 #20
20230365711
2023-11-16

ANTI-CEA ANTIBODIES

 #21
20230338525
2023-10-26

VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER

 #22
20230330226
2023-10-19

COMPOSITIONS AND METHODS FOR THE PREVENTION OF TYPE I HYPERSENSITIVITY REACTIONS

 #23
20230310595
2023-10-05

USE OF RILUZOLE, RILUZOLE PRODRUGS OR RILUZOLE ANALOGS WITH IMMUNOTHERAPIES TO TREAT CANCERS

 #24
20230285574
2023-09-14

CONJUGATES OF BIOLOGICALLY ACTIVE MOLECULES TO FUNCTIONALIZED POLYMERS

 #25
20230277665
2023-09-07

Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody

 #26
20230174662
2023-06-08

METHODS OF TREATING CASTRATE-RESISTANT PROSTATE CANCER

 #27
20230105714
2023-04-06

ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS

 #28
20230022913
2023-01-26

Conjugates of tumor necrosis factor inhibitors to functionalized polymers

 #29
20230014352
2023-01-19

INHALED STATINS AS BRONCHODILATORS TO IMPROVE LUNG FUNCTION IN RESPIRATORY DISEASES

 #30
20220409725
2022-12-29

Multispecific antigen-binding proteins

 #31
20220347236
2022-11-03

Composition comprising probiotics and polypeptide having binding affinity for IgE and use thereof

 #32
20220340687
2022-10-27

METHODS OF TREATMENT USING OMALIZUMAB

 #33
20220323582
2022-10-13

HUMAN ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AGAINST CD74

 #34
20220296718
2022-09-22

EXCIPIENT FOR BIOTHERAPEUTICS

 #35
20220289836
2022-09-15

Anti-PACAP antibodies and uses thereof

 #36
20220273595
2022-09-01

COMPOSITIONS AND METHODS FOR TREATING ECZEMA

 #37
20220257762
2022-08-18

Anti-LAG3 antibodies and antigen-binding fragments

 #38
20220249664
2022-08-11

METHODS OF TREATING AUTOIMMUNE AND ALLOIMMUNE DISORDERS

 #39
20220241287
2022-08-04

COMBINATION THERAPIES

 #40
20220177604
2022-06-09

ANTI-IgE ANTIBODIES

 #41
20220168419
2022-06-02

COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS

 #42
20220133889
2022-05-05

COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3

 #43
20220096545
2022-03-31

NANOPARTICLE FORMULATIONS

 #44
20220080034
2022-03-17

Genetically modified anti-third party central memory T cells and use of same in immunotherapy

 #45
20220073648
2022-03-10

INFLUENZA VACCINES AND METHODS OF USE THEREOF

 #46
20220031856
2022-02-03

Conjugates of tumor necrosis factor inhibitors to functionalized polymers

 #47
20220002441
2022-01-06

ANTI-CEA ANTIBODIES

 #48
20210346482
2021-11-11

SUBSTANCES, VACCINES AND METHODS FOR DIAGNOSING AND REDUCING INCIDENCES OF TRANSPLANT REJECTION

 #49
20210338827
2021-11-04

Compounds and methods for diagnosis and treatment of viral infections

 #50
20210324079
2021-10-21

BISPECIFIC HER2 AND CD3 BINDING MOLECULES

 #51
20210324068
2021-10-21

Screening method for identifying anti-PACAP antibodies or antibody fragments suitable for use in treating or preventing PACAP-associated photophobia or light aversion

 #52
20210301005
2021-09-30

Isoform-selective anti-TGFβ antibodies and methods of use

 #53
20210283266
2021-09-16

Conjugates of biologically active molecules to functionalized polymers

 #54
20210277106
2021-09-09

Methods of treatment with anti-PACAP antibodies

 #55
20210246442
2021-08-12

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING LUPUS

 #56
20210221884
2021-07-22

ANTI-PACAP ANTIBODIES

 #57
20210220328
2021-07-22

PYRROLE DERIVATIVES AS ACC INHIBITORS

 #58
20210206860
2021-07-08

ANTI-FLT-1 ANTIBODIES FOR TREATING DUCHENNE MUSCULAR DYSTROPHY

 #59
20210169955
2021-06-10

Use of Oncolytic Herpes Simplex Virus, Alone or in Combination with Immune Check-Point Inhibitor, in the Treatment of Cancer

 #60
20210070884
2021-03-11

Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)

 #61
20210054084
2021-02-25

Anti-CD25 antibody agents

 #62
20210047420
2021-02-18

Anti-CD25 for tumour specific cell depletion

 #63
20210046183
2021-02-18

COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF IMMUNE COMPLEX DISEASE

 #64
20210040221
2021-02-11

Anti-CD25 for tumour specific cell depletion

 #65
20210017276
2021-01-21

Anti-TIGIT antibodies

 #66
20210009704
2021-01-14

Anti-CD25 for tumour specific cell depletion

 #67
20210009703
2021-01-14

Anti-CD25 for tumour specific cell depletion

 #68
20210009702
2021-01-14

Anti-CD25 for tumour specific cell depletion

 #69
20210009699
2021-01-14

Anti-CD25 antibody agents

 #70
20210000837
2021-01-07

Heterocyclic compounds and uses thereof

 #71
20200407454
2020-12-31

Anti-CD25 antibody agents

 #72
20200399357
2020-12-24

Anti-NGF Antibodies for Treatment of Various Disorders

 #73
20200377953
2020-12-03

THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASES

 #74
20200345856
2020-11-05

Conjugates of tumor necrosis factor inhibitors to functionalized polymers

 #75
20200323966
2020-10-15

COMBINATION THERAPIES COMPRISING DENDRITIC CELLS-BASED VACCINE AND IMMUNE CHECKPOINT INHIBITOR

 #76
20200317816
2020-10-08

REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIa ANTIBODIES AND USES THEREOF

 #77
20200306375
2020-10-01

COMPOSITIONS AND METHODS FOR TUMOR TRANSDUCTION

 #78
20200289661
2020-09-17

CD48 ANTIBODIES AND CONJUGATES THEREOF

 #79
20200222546
2020-07-16

Conjugates of biologically active molecules to functionalized polymers

 #80
20200222464
2020-07-16

Nanoparticle formulations

 #81
20200197517
2020-06-25

Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody

 #82
20200172612
2020-06-04

Anti-PACAP antibodies

 #83
20200150832
2020-05-14

Image selection suggestions

 #84
20200129487
2020-04-30

CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND

 #85
20200085947
2020-03-19

Vista modulators for diagnosis and treatment of cancer

 #86
20200079847
2020-03-12

Anti-PACAP antibodies

 #87
20200078426
2020-03-12

TREATMENT OF CANCER BY INFUSION OF ONCOLYTIC HERPES SIMPLEX VIRUS TO THE BLOOD

 #88
20200009261
2020-01-09

Conjugates of tumor necrosis factor inhibitors to functionalized polymers

 #89
20190358323
2019-11-28

HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS

 #90
20190322752
2019-10-24

Anti-CD25 antibody agents

 #91
20190300613
2019-10-03

Anti-CD25 antibody agents

 #92
20190300607
2019-10-03

COMPOSITION CONTAINING ANTI-ROBO4 ANTIBODY AND OTHER AGENTS

 #93
20190290759
2019-09-26

COMBINATION OF HDAC INHIBITOR AND ANTI-PD-L1 ANTIBODY FOR TREATMENT OF OVARIAN CANCER

 #94
20190290619
2019-09-26

Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers

 #95
20190290605
2019-09-26

Compositions and methods for treating eczema

 #96
20190284287
2019-09-19

Anti-CD25 antibody agents

 #97
20190276531
2019-09-12

Anti-TIM-3 antibodies and compositions

 #98
20190276523
2019-09-12

Composition and methods of treating B cell disorders

 #99
20190270807
2019-09-05

Methods of determining whether anti-PACAP antibodies inhibit PACAP-associated photophobia or light aversion

 #100
20190231875
2019-08-01

REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS

 #101
20190216816
2019-07-18

Combination therapies

 #102
20190209701
2019-07-11

COMBINATION THERAPY WITH A MEK INHIBITOR, A PD-1 AXIS INHIBITOR, AND A TAXANE

 #103
20190185583
2019-06-20

ANTI-CEA ANTIBODIES

 #104
20190175731
2019-06-13

USE OF GLUTAMATE MODULATING AGENTS WITH IMMUNOTHERAPIES TO TREAT CANCER

 #105
20190151444
2019-05-23

Desensitizing mast cells by co-presentation of antigens with high affinity mast cell siglec ligands

 #106
20190125887
2019-05-02

Conjugates of biologically active molecules to functionalized polymers

 #107
20190120854
2019-04-25

Method of treating asthma using an IL-13 antibody

 #108
20190091332
2019-03-28

Anti-LAG3 antibodies and antigen-binding fragments

 #109
20190083615
2019-03-21

Anti-LAG3 antibodies and antigen-binding fragments

 #110
20190083614
2019-03-21

Anti-LAG3 antibodies and antigen-binding fragments

 #111
20190040154
2019-02-07

METHODS AND COMPOSITIONS FOR TREATMENT OF IMMUNE-RELATED DISEASES OR DISORDERS AND/OR THERAPY MONITORING

 #112
20190022100
2019-01-24

ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF

 #113
20190022092
2019-01-24

Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist

 #114
20180371083
2018-12-27

Anti-TIGIT antibodies

 #115
20180369402
2018-12-27

Conjugates of tumor necrosis factor inhibitors to functionalized polymers

 #116
20180320174
2018-11-08

Compositions and methods for treating or preventing lupus

 #117
20180318419
2018-11-08

COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS

 #118
20180311348
2018-11-01

Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition

 #119
20180273626
2018-09-27

OMALIZUMAB RESISTANT IGE VARIANTS AND THEIR USE IN ANTI-IGE THERAPY

 #120
20180273623
2018-09-27

Bispecific HER2 and CD3 binding molecules

 #121
20180214550
2018-08-02

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING NK CELL KILLING ACTIVITIES

 #122
20180207273
2018-07-26

COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3

 #123
20180207272
2018-07-26

Genetically modified anti-third party central memory T cells and use of same in immunotherapy

 #124
20180207271
2018-07-26

IL-26 inhibitors

 #125
20180207247
2018-07-26

Methods of transplantation and disease treatment

 #126
20180207212
2018-07-26

Use of oncolytic herpes simplex virus, alone or in combination with immune check-point inhibitor, in the treatment of cancer

 #127
20180200300
2018-07-19

Methods of transplantation and disease treatment

 #128
20180194841
2018-07-12

Methods for tumor treatment using CD3XCD20 bispecific antibody

 #129
20180177873
2018-06-28

Multispecific antigen-binding proteins

 #130
20180169240
2018-06-21

METHODS OF TREATING AUTOIMMUNE AND ALLOIMMUNE DISORDERS

 #131
20180161429
2018-06-14

CANCER THERAPY TARGETING TETRASPANIN 33 (TSPAN33) IN MYELOID DERIVED SUPPRESSOR CELLS

 #132
20180155419
2018-06-07

ANTI-MIF ANTIBODIES IN THE TREATMENT OF CANCERS CONTAINING MUTANT TP53 AND/OR MUTANT RAS

 #133
20180153939
2018-06-07

Nanoparticle formulations

 #134
20180099048
2018-04-12

Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same

 #135
20180092984
2018-04-05

CD48 antibodies and conjugates thereof

 #136
20180079827
2018-03-22

ANTI-CEA ANTIBODIES

 #137
20180072806
2018-03-15

Anti-Flt-1 antibodies for treating duchenne muscular dystrophy

 #138
20180071247
2018-03-15

Combination of a PD-1 antagonist and eribulin for treating cancer

 #139
20180055852
2018-03-01

Heterocyclic compounds and uses thereof

 #140
20180043015
2018-02-15

Methods for diagnosing and reducing incidences of cardiac allograft rejection

 #141
20180022825
2018-01-25

Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof

 #142
20170355781
2017-12-14

ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE (CEACAM)

 #143
20170290914
2017-10-12

ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS

 #144
20170275617
2017-09-28

Compositions and methods for treating or preventing lupus

 #145
20170267759
2017-09-21

Anti-LAG3 antibodies and antigen-binding fragments

 #146
20170198061
2017-07-13

INFLUENZA VACCINES AND METHODS OF USE THEREOF

 #147
20170173151
2017-06-22

HUMAN ANTIBODIES AND ANTIBODY-DRUG CONJUGATES AGAINST CD74

 #148
20170112929
2017-04-27

VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER

 #149
20170107300
2017-04-20

METHODS AND COMPOSITIONS FOR TREATMENT OF IMMUNE-RELATED DISEASES OR DISORDERS AND/OR THERAPY MONITORING

 #150
20170073431
2017-03-16

Humanized monoclonal antibodies and methods of use

 #151
20170066819
2017-03-09

ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS

 #152
20170049888
2017-02-23

HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS

 #153
20160367675
2016-12-22

REDUCED-VISCOSITY CONCENTRATED PROTEIN FORMULATIONS

 #154
20160363597
2016-12-15

Cell lines expressing surface bound anti-idiotype antibodies against anti-CD22 antibodies and uses thereof

 #155
20160362488
2016-12-15

ANTI-PACAP ANTIBODIES AND USES THEREOF

 #156
20160361441
2016-12-15

Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia

 #157
20160354477
2016-12-08

Conjugates of tumor necrosis factor inhibitors to functionalized polymers

 #158
20160347825
2016-12-01

Optimized Fc variants and methods for their generation

 #159
20160318993
2016-11-03

Optimized Fc variants and methods for their generation

 #160
20160304604
2016-10-20

Anti-PACAP antibodies

 #161
20160296638
2016-10-13

Gene therapy to prevent reactions to allergens

 #162
20160229923
2016-08-11

ANTI-CEA ANTIBODIES

 #163
20160129006
2016-05-12

Antiviral compounds and methods of use thereof

 #164
20160009810
2016-01-14

Methods of administering IgG1 antibodies and methods of suppressing angiogenesis

 #165
20150368333
2015-12-24

TNF-ALPHA ANTIGEN-BINDING PROTEINS

 #166
20150290207
2015-10-15

Heterocyclic compounds and uses thereof

 #167
20150246125
2015-09-03

Methods and compositions for suppressing IgE-mediated anaphylaxis

 #168
20150225485
2015-08-13

High concentration antibody and protein formulations

 #169
20150216973
2015-08-06

METHOD FOR THE INDUCTION OF AN IMMUNE RESPONSE

 #170
20150175711
2015-06-25

Anti-CD22 anti-idiotypic antibodies and uses thereof

 #171
20150166678
2015-06-18

Compositions and methods comprising binding proteins for adalimumab

 #172
20150147345
2015-05-28

Conjugates of biologically active molecules to functionalized polymers

 #173
20150110784
2015-04-23

THERAPEUTIC COMBINATIONS AND METHODS INCLUDING IRM COMPOUNDS

 #174
20150079082
2015-03-19

Optimized Fc variants and methods for their generation

 #175
20150044198
2015-02-12

Reduced-viscosity concentrated protein formulations

 #176
20140294829
2014-10-02

ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS

 #177
20140286942
2014-09-25

Methods for treating chronic obstructive pulmonary disease

 #178
20140271618
2014-09-18

Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)

 #179
20140220042
2014-08-07

C(epsilon)mX peptides for inducing immune responses to human mIgE on B lymphocytes

 #180
20140186341
2014-07-03

Methods for improving drug efficacy including a combination of drug administration and nerve modulation

 #181
20140141020
2014-05-22

ANTI-CD3 THERAPIES

 #182
20140127199
2014-05-08

Compositions and methods for treating or preventing lupus

 #183
20140105912
2014-04-17

VISTA modulators for diagnosis and treatment of cancer

 #184
20140044702
2014-02-13

Diagnosis and treatments relating to TH2 inhibition

 #185
20140044645
2014-02-13

Diagnosis and treatments relating to TH2 inhibition

 #186
20140037615
2014-02-06

MATERIALS AND METHODS FOR DESIGNING AUTOLOGOUS IDIOTYPE VACCINES AND TREATMENT OF B-CELL MALIGNANCIES

 #187
20140030278
2014-01-30

Conjugates of tumor necrosis factor inhibitors to functionalized polymers

 #188
20130302314
2013-11-14

Anti-CεmX antibodies capable of binding to human mIgE on B lymphocytes

 #189
20130243750
2013-09-19

ANTI-IGE ANTIBODIES AND METHODS USING SAME

 #190
20130243749
2013-09-19

Humanized monoclonal antibodies and methods of use

 #191
20130156758
2013-06-20

Optimized Fc variants and methods for their generation

 #192
20130156754
2013-06-20

Optimized FC variants and methods for their generation

 #193
20130071353
2013-03-21

Antiviral compounds and methods of use thereof

 #194
20130004495
2013-01-03

ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS

 #195
20120251529
2012-10-04

Anti-CEA antibodies

 #196
20120230980
2012-09-13

Optimized Fc variants and methods for their generation

 #197
20120207746
2012-08-16

Anti-CεmX antibodies capable of binding to human mIgE on B lymphocytes

 #198
20120156194
2012-06-21

DIAGNOSIS AND TREATMENTS RELATING TO TH2 INHIBITION

 #199
20120114622
2012-05-10

and weight control

 #200
20120076783
2012-03-29

Reduced-viscosity concentrated protein formulations

 #201
20120070431
2012-03-22

Methods for treating chronic obstructive pulmonary disease

 #202
20120064086
2012-03-15

High concentration antibody and protein formulations

 #203
20120020979
2012-01-26

Methods for treating IgE-mediated disorder

 #204
20110268725
2011-11-03

Anti-NGF antibodies for the treatment of various disorders

 #205
20100297008
2010-11-25

Ganglioside associated recombinant antibodies and the use thereof in the treatment of tumors

 #206
20100254990
2010-10-07

ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS

 #207
20100247524
2010-09-30

Methods for treating Chronic Obstructive Pulmonary Disease

 #208
20100040625
2010-02-18

Pharmaceutical Compositions Containing Monoclonal Anti-Idiotypic Anti-Ca-125 Antibody and Aluminium Derivatives

 #209
20090280129
2009-11-12

HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS

 #210
20090263381
2009-10-22

COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH AN ANTI-IGE ANTIBODY FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE

 #211
20090220496
2009-09-03

Methods to treating chronic obstructive pulmonary disease

 #212
20090191268
2009-07-30

ALLERGY VACCINES

 #213
20090104184
2009-04-23

Pharmaceutical compositions containing monoclonal anti idiotypic anti-CA-125 antibody and aluminium

 #214
20090092599
2009-04-09

Optimized Fc variants and methods for their generation

 #215
20090081208
2009-03-26

Optimized Fc variants and methods for their generation

 #216
20090068177
2009-03-12

Optimized Fc variants and methods for their generation

 #217
20090068172
2009-03-12

Compositions and methods comprising binding proteins for adalimumab

 #218
20080241069
2008-10-02

Methods and compositions for treating IgE-mediated diseases

 #219
20080206237
2008-08-28

Synergistic Combination Of Xolair/Omalizumab/E25 With Immunosuppressive Agent

 #220
20080003218
2008-01-03

Anti-IgE antibodies

 #221
20070286855
2007-12-13

IMPROVING TREATMENTS

 #222
20070053900
2007-03-08

HIGH CONCENTRATION ANTIBODY AND PROTEIN FORMULATIONS

 #223
20060240000
2006-10-26

Combination treatments for allergic disease comprising administering an anti-IgE antibody and antiallergic compound

 #224
20060083743
2006-04-20

Method of cancer therapy by in situ production of F5 antibodies

 #225
20060018911
2006-01-26

Design of therapeutics and therapeutics

 #226
20060013811
2006-01-19

Methods of treating IgE-associated disorders and compositions for use therein

 #227
20050271649
2005-12-08

Therapeutic adjuvant

 #228
20050171072
2005-08-04

Therapeutic combinations and methods including IRM compounds

 #229
20050069535
2005-03-31

Immunotherapeutic combinations for the treatment of tumours that overexpress gangliosides

 #230
20050042215
2005-02-24

Combination treatments for allergic disease comprising administering an anti-ige antibody and antiallergic compound